Clinical Trials Logo

Type2 Diabetes clinical trials

View clinical trials related to Type2 Diabetes.

Filter by:

NCT ID: NCT03964428 Completed - Periodontitis Clinical Trials

Serum Ferritin and Hepicidin Concentration in Chronic Periodontitis Patients With T2DM

Start date: September 1, 2018
Phase:
Study type: Observational

serum level of ferritin and hepicidin were evaluated in periodontitis patient with and without type 2 diabetes before and after non surgical periodontal treatment to clarify their in periodontal disease

NCT ID: NCT03958838 Completed - PreDiabetes Clinical Trials

Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities

Start date: May 25, 2019
Phase: N/A
Study type: Interventional

This project will disseminate a community-level intervention that integrates peer support from Community Self-Management Groups (CSMGs) and primary care through Community Health Centers (CHC). The model and program materials were developed and refined from the first year of implementation within community health centers in Shanghai. This project will be implemented in 12 communities in 6 districts across Shanghai, representing a diverse cross section of the population. A total of 1440 subjects will be recruited from the 12 intervention communities and 720 control subjects will be recruited from 4 control communities.

NCT ID: NCT03955952 Completed - Obesity Clinical Trials

Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes

Start date: June 5, 2019
Phase:
Study type: Observational

The objective of the analysis was to evaluate the relationship between bariatric surgery and cardiovascular outcomes in obese patients with type 2 diabetes. This is a retrospective matched cohort study of patients with diabetes that underwent bariatric surgery at the Cleveland Clinic between 2004-2017. Each bariatric patient was matched to a non-surgical control with obesity and type 2 diabetes in a 1:5 ratio using data from the Electronic Medical Record (EMR). The maximum observation time was 10 years. Cumulative incidence rates for all-cause mortality and cardiovascular events were calculated at years 1, 3, 5, 7 and 10. Kaplan-Meier curves were created for all the outcomes with all-cause mortality considered as a completing risk.

NCT ID: NCT03950505 Recruiting - Type2 Diabetes Clinical Trials

To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes

Start date: May 29, 2020
Phase: Phase 4
Study type: Interventional

This study was designed to evaluate the effect of Nesinaact on non-alcoholic steatohepatitis through magnetic resonance imaging (MRI)-based proton density-fat fraction (MRI-PDFF) and liver fibroscan in patients with type 2 diabetes. This is a prospective, open-label, single-arm, single-center clinical Study. After 24 weeks of Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment, the improvement of parameters estimated by MRI and liver fibroscan will be estimated.

NCT ID: NCT03944200 Completed - Type2 Diabetes Clinical Trials

A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State

Start date: February 7, 2019
Phase: Phase 1
Study type: Interventional

A study demonstrates the bioequivalence of DA-1229_01(A) at Fed State when compared with Sugamet sustained-release(SR) Tab 5/1000mg® in healthy adults

NCT ID: NCT03939624 Completed - Heart Failure Clinical Trials

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Start date: October 1, 2018
Phase:
Study type: Observational

The purpose of this study is to compare the risk of cardiovascular events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes. The investigators will carry out separate population-based cohort studies using health care databases in seven Canadian provinces and the United Kingdom. The study cohort will be defined by the initiation of a SGLT2 inhibitor or a DPP-4 inhibitor after SGLT2 inhibitors entered the market. Patients will be followed up until the occurrence of a cardiovascular event. The results from the separate sites will be combined by meta-analysis to provide an overall assessment of the risk of cardiovascular events in users of SGLT2 inhibitors. The investigators hypothesize that the use of SGLT2 inhibitors will be associated with a decreased risk of cardiovascular events in comparison with the use of DPP-4 inhibitors.

NCT ID: NCT03939143 Completed - Type2 Diabetes Clinical Trials

A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State

Start date: February 7, 2019
Phase: Phase 1
Study type: Interventional

A study demonstrates the bioequivalence of DA-1229_01(A) at Fasting State when compared with Sugamet sustained-release(SR) Tab 5/1000mg® in healthy adults

NCT ID: NCT03933696 Recruiting - Alzheimer Disease Clinical Trials

Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

Start date: January 2, 2019
Phase: N/A
Study type: Interventional

To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).

NCT ID: NCT03923205 Recruiting - Healthy Clinical Trials

Assessing the Effects of a Buckwheat Beverage on Postprandial Glucose Metabolism on Healthy and T2D Individuals

BUCKFOOD
Start date: March 7, 2019
Phase: N/A
Study type: Interventional

Buckwheat is a unique crop because is naturally rich in compounds that have shown beneficial effects on glucose metabolism. A constant high glucose level in blood after meal consumption is an independent risk factor for cardiovascular complications and death. In order to prevent Type 2 Diabetes Mellitus (T2D) and/or its complications it is important to have a strict control of the blood glucose levels after a meal. There are known therapies for the control of the high glucose blood levels such as agents that act on intestinal digestion of carbohydrates and therapeutic agents that mimic the insulin response after a meal. The combination of these type of agents was commonly prescribed in the treatment of T2D. The aim of the study is to assess the effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet.

NCT ID: NCT03910361 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Start date: April 12, 2019
Phase: Phase 4
Study type: Interventional

A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases